EGFR and non-small cell lung carcinoma: Compared with the previous models of BM, the new prognostic system (EGFR-RPA) can accurately classify or categorize patients according to their prognosis, which can be used to determine optimal and personalized management of patients with EGFR-mutated NSCLC who develop BM.